{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:21:45Z","timestamp":1778070105097,"version":"3.51.4"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:p>\n                    A topical 0.05% cyclosporine A (CsA) nanoemulsion formulation was developed to improve tolerability and efficacy. However, its role in preventing recurrence and improving ocular surface parameters after pterygium surgery remains unclear. This study aimed to compare the efficacy and safety of 2 different topical 0.05% CsA formulations following pterygium excision with conjunctival autograft. This retrospective comparative study included patients who underwent pterygium excision with conjunctival autograft using fibrin glue by a single surgeon between January 2021 and June 2024. Postoperatively, patients were administered either 0.05% CsA emulsion (CsA-E;\n                    <jats:italic toggle=\"yes\">Restasis\u00ae<\/jats:italic>\n                    , Allergan Inc., Irvine) or 0.05% CsA nanoemulsion (CsA-NE;\n                    <jats:italic toggle=\"yes\">Cyporin N\u00ae<\/jats:italic>\n                    , Taejoon Pharm Co., Ltd., Seoul, Republic of Korea) twice daily for 12 months. The primary outcome was the recurrence rate of pterygium at 12 months postoperative. Secondary outcomes included uncorrected (UDVA) and corrected (CDVA) distance visual acuity, tear meniscus height (TMH), and adverse events. A total of 202 eyes (202 patients) was analyzed: 96 in the CsA-E group (60 males, 36 females; mean age, 65.6\u2005\u00b1\u20058.2 years) and 106 in the CsA-NE group (64 males, 42 females; mean age, 65.2\u2005\u00b1\u20058.4 years). There were no significant differences in baseline characteristics between the 2 groups. The recurrence rate was 8.3% in the CsA-E group and 3.8% in the CsA-NE group, with no statistically significant difference (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.235). Postoperative VA outcomes were comparable between the groups; the median CDVA was 0.04 logMAR in both groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.175). Notably, TMH values in both groups significantly decreased compared to baseline (both\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001), normalizing to within the physiological range, with no significant difference in the magnitude of reduction between the groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.641). No severe adverse events were reported in either group. Both CsA formulations were effective in preventing pterygium recurrence with comparable safety profiles. Additionally, both groups achieved excellent and comparable postoperative VA.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047941","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:00:56Z","timestamp":1773432056000},"page":"e47941","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of two different topical 0.05% cyclosporine A formulations on ocular surface outcomes following pterygium excision with conjunctival autograft"],"prefix":"10.1097","volume":"105","author":[{"given":"Soyoung","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Kim\u2019s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Young","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kim\u2019s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kookyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kim\u2019s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hungwon","family":"Tchah","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kim\u2019s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-6423","authenticated-orcid":false,"given":"Kyungmin","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kim\u2019s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260506","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2025.06.020","article-title":"Adjuvant use of topical 0.05% cyclosporine A in primary pterygium recurrence rate: a systematic review and meta-analysis.","volume":"278","author":"Aleksander-Ivanov","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R2-20260506","first-page":"25158414211020152","article-title":"Pterygium: an update on pathophysiology, clinical features, and management.","volume":"13","author":"Shahraki","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ICL.0000000000001178","article-title":"Postoperative outcomes regarding tear film changes and dry eye symptoms in primary pterygium excision with conjunctival autograft.","volume":"51","author":"Zatarain-Barr\u00f3n","year":"2025","journal-title":"Eye Contact Lens"},{"key":"R4-20260506","first-page":"CD011308","article-title":"Fibrin glue versus sutures for conjunctival autografting in primary pterygium surgery.","volume":"12","author":"Romano","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s10792-023-02635-z","article-title":"Autologous fibrin glue versus sutures for conjunctival autograft in primary pterygium: a randomized clinical trial.","volume":"43","author":"Cioba","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"400","DOI":"10.18502\/jovr.v14i4.5437","article-title":"Topical tacrolimus as an adjunct to conventional therapy for stromal herpetic keratitis: a randomized clinical trial.","volume":"14","author":"Akbari","year":"2019","journal-title":"J Ophthalmic Vis Res"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/ICO.0000000000000477","article-title":"Cyclosporine A downregulates MMP-3 and MMP-13 expression in cultured pterygium fibroblasts.","volume":"34","author":"Kim","year":"2015","journal-title":"Cornea"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s40123-025-01217-9","article-title":"Assessment the SAFETY of CyclASol compared with vehicle and commercially available 0.05% cyclosporine in dry eye disease: a systematic review and meta-analysis.","volume":"14","author":"Ballesteros-S\u00e1nchez","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1590\/S0004-27492006000600010","article-title":"Exposure of Tenon\u2019s capsule fibroblasts of pterygium to cyclosporin 0.05%.","volume":"69","author":"Hercules","year":"2006","journal-title":"Arq Bras Oftalmol"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10792-015-0106-2","article-title":"In vitro study of cyclosporine A 0.05% on primary and recurrent pterygium fibroblasts.","volume":"36","author":"Viveiros","year":"2016","journal-title":"Int Ophthalmol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bjophthalmol-2017-310288","article-title":"Comparison among adjuvant treatments for primary pterygium: a network meta-analysis.","volume":"102","author":"Fonseca","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3341\/kjo.2018.0116","article-title":"Efficacy of topical cyclosporine nanoemulsion 0.05% compared with topical cyclosporine emulsion 0.05% and diquafosol 3% in dry eye.","volume":"33","author":"Park","year":"2019","journal-title":"Korean J Ophthalmol"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"6037401","DOI":"10.1155\/2022\/6037401","article-title":"Comparison of consecutive therapeutic effects of nanoemulsion and emulsion cyclosporin in dry eye patients after short-term treatment with topical fluorometholone.","volume":"2022","author":"Choi","year":"2022","journal-title":"J Ophthalmol"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10384-022-00906-3","article-title":"Efficacy of a 0.05% cyclosporine A topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction.","volume":"66","author":"Rhim","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.18240\/ijo.2022.12.05","article-title":"Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction.","volume":"15","author":"Jo","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12886-024-03620-5","article-title":"Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes: objective and subjective evaluation.","volume":"24","author":"Moon","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"e0224805","DOI":"10.1371\/journal.pone.0224805","article-title":"Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.","volume":"14","author":"Bang","year":"2019","journal-title":"PLoS One"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/jop.2024.0169","article-title":"Safety and efficacy of 0.1% cyclosporine solutions in dry eye syndrome: a systematic review and meta-analysis of randomized clinical trials.","volume":"41","author":"Aleksander-Ivanov","year":"2025","journal-title":"J Ocul Pharmacol Ther"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.7.5.24","article-title":"Once-daily cyclosporine-A-MiDROPS for treatment of dry eye disease.","volume":"7","author":"Coursey","year":"2018","journal-title":"Transl Vis Sci Technol"},{"key":"R20-20260506","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/17425247.2016.1218462","article-title":"From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS).","volume":"14","author":"Rehman","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"R21-20260506","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jop.2022.0119","article-title":"A multicenter, randomized, double-blind evaluation of the efficacy of TJO-087 versus 0.05% cyclosporine A in moderate to severe dry eye.","volume":"39","author":"Eom","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"R22-20260506","doi-asserted-by":"crossref","first-page":"5935239","DOI":"10.1155\/2019\/5935239","article-title":"Tear film instability and meibomian gland dysfunction correlate with the pterygium size and thickness pre- and postexcision in patients with pterygium.","volume":"2019","author":"Li","year":"2019","journal-title":"J Ophthalmol"},{"key":"R23-20260506","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3341\/kjo.2025.0003","article-title":"Treatment of pterygium on the refractive errors: a systematic review.","volume":"39","author":"Rad","year":"2025","journal-title":"Korean J Ophthalmol"},{"key":"R24-20260506","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10792-025-03770-5","article-title":"Recurrence-free time after pterygium surgery with sutureless conjunctival-limbal vs. conjunctival graft: is there still a role for conjunctival graft alone?","volume":"45","author":"Lucentini","year":"2025","journal-title":"Int Ophthalmol"},{"key":"R25-20260506","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtos.2016.12.001","article-title":"Femtosecond laser-assisted conjunctival autograft preparation for pterygium surgery.","volume":"15","author":"Fuest","year":"2017","journal-title":"Ocul Surf"},{"key":"R26-20260506","first-page":"2661","article-title":"Long-term surgical outcome of pterygium excision and conjunctival limbal autograft: minimum 11 years follow-up study in a country with high ultraviolet exposure.","volume":"18","author":"Jammal","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R27-20260506","doi-asserted-by":"crossref","first-page":"1522167","DOI":"10.3389\/fmed.2025.1522167","article-title":"Modified protocol for pterygium surgery without blades and electrocoagulation.","volume":"12","author":"Ge","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R28-20260506","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bjo.2003.032854","article-title":"Cut and paste: a no suture, small incision approach to pterygium surgery.","volume":"88","author":"Koranyi","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R29-20260506","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/ojo.OJO_6_2017","article-title":"Pterygium excision and conjunctival autograft: a comparative study of techniques.","volume":"11","author":"Kumar","year":"2018","journal-title":"Oman J Ophthalmol"},{"key":"R30-20260506","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000151740","article-title":"Topical cyclosporine A in the prevention of pterygium recurrence.","volume":"222","author":"Yalcin Tok","year":"2008","journal-title":"Ophthalmologica"},{"key":"R31-20260506","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3341\/kjo.2015.29.6.375","article-title":"A comparative study of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery.","volume":"29","author":"Hwang","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"R32-20260506","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/OPTH.S19469","article-title":"The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery.","volume":"5","author":"Turan-Vural","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"R33-20260506","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00003226-200403000-00002","article-title":"Effect of pterygium surgery on corneal topography: a prospective study.","volume":"23","author":"Bahar","year":"2004","journal-title":"Cornea"},{"key":"R34-20260506","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4103\/ijo.IJO_1921_18","article-title":"A comparative study of preoperative and postoperative changes in corneal astigmatism after pterygium excision by different techniques.","volume":"67","author":"Garg","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R35-20260506","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/ICL.0000000000000143","article-title":"Corneal wavefront aberrations after primary and recurrent pterygium surgery.","volume":"41","author":"Ozgurhan","year":"2015","journal-title":"Eye Contact Lens"},{"key":"R36-20260506","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41433-022-02281-2","article-title":"Repeatability, reproducibility and agreement between three different diagnostic imaging platforms for tear film evaluation of normal and dry eye disease.","volume":"37","author":"Singh","year":"2023","journal-title":"Eye (Lond)"},{"key":"R37-20260506","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/ijo.IJO_743_16","article-title":"Evaluation of meibomian gland and tear film changes in patients with pterygium.","volume":"65","author":"Ye","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R38-20260506","doi-asserted-by":"crossref","first-page":"102281","DOI":"10.1016\/j.clae.2024.102281","article-title":"Ocular surface parameters repeatability and agreement \u2013 a comparison between Keratograph 5M and IDRA.","volume":"47","author":"Yin Chan","year":"2024","journal-title":"Cont Lens Anterior Eye"},{"key":"R39-20260506","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/nnm-2023-0364","article-title":"Studies on cationic ocular emulsions containing bipartitioned oil droplets to codeliver cyclosporin A and etodolac.","volume":"19","author":"Ruhina Rahman","year":"2024","journal-title":"Nanomedicine (Lond)"},{"key":"R40-20260506","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ICO.0b013e31825e83f4","article-title":"Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.","volume":"32","author":"Daull","year":"2013","journal-title":"Cornea"},{"key":"R41-20260506","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge.","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur J Pharm Biopharm"},{"key":"R42-20260506","doi-asserted-by":"crossref","first-page":"26439","DOI":"10.1038\/s41598-025-12300-3","article-title":"Astigmatism-type-specific impact of peripheral corneal thickness on anterior keratometric profile changes after temporal clear corneal incision cataract surgery.","volume":"15","author":"Oh","year":"2025","journal-title":"Sci Rep"},{"key":"R43-20260506","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/MD.0000000000000518","article-title":"Analysis of recurrence patterns following pterygium surgery with conjunctival autografts.","volume":"94","author":"Kwon","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R44-20260506","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1038\/s41598-025-94724-5","article-title":"Impact of pterygium morphological profiles on dry eye parameters.","volume":"15","author":"Ha","year":"2025","journal-title":"Sci Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:06:06Z","timestamp":1778069166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047941","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}